Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Prolia Denosumab Coverage Update | OpenPayer
    Ask Trek AI about this page
    RetiredHawaii Medical Service Association (HMSA)Policy N/A

    Prolia (denosumab) and Denosumab Biosimilars

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization for Prolia and denosumab biosimilar products used for osteoporosis, prevention of osteoporosis, glucocorticoid-induced osteoporosis, and treatment-related bone loss associated with prostate or breast cancer therapy for HMSA Medicare Advantage members.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyProlia (denosumab) and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOct 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the HMSA medical specialty drug policy website using the applicable fax form.
    SourceLink
    POLICY UPDATE CHANGES

    A preferred product grid and criteria were added.

    9Denosumab products named
    5FDA-approved indication categories
    3Compendial use categories
    24 monthsAuthorization for select indications

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredPrior authorization

    Covered Indications

    FDA-Approved Indications

    Covered when the member meets at least one FDA-approved indication below, all applicable approval criteria are met, and the member has no exclusions to the prescribed therapy.

    ONE of the following FDA-approved indications

    • Treatment of postmenopausal women with osteoporosis at high risk for fracture.

      High risk for fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy.

    • Treatment to increase bone mass in men with osteoporosis at high risk for fracture.

      High risk for fracture is defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy.

    • Treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture who are initiating or continuing systemic glucocorticoids at a daily dosage equivalent to 7.5 mg or greater of prednisone and are expected to remain on glucocorticoids for at least 6 months.
    • Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
    • Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer.

    Compendial Uses

    Covered for the following compendial uses. All other indications will be assessed on an individual basis and must be supported by evidence from Medicare-approved compendia.

    ONE of the following compendial uses

    • Prophylaxis of osteoporosis in osteopenic postmenopausal women.
    • Treatment-related bone loss in patients with prostate cancer receiving androgen deprivation therapy (ADT).
    • Treatment in postmenopausal (natural or induced) patients with breast cancer receiving adjuvant aromatase inhibition therapy to maintain or improve bone mineral density and reduce risk of fractures.
    • An indication other than those listed in the coverage criteria, supported by evidence from Medicare-approved compendia.

      Individual assessment is required.

    Osteoporosis Treatment

    Indefinite authorization may be granted when all of the following are met:

    ALL of the following

    • The member is a man or postmenopausal woman with osteoporosis.
    • The member is at high risk for fracture.

    Osteoporosis Prevention

    Indefinite authorization may be granted when all of the following are met:

    ALL of the following

    • The member is a postmenopausal woman with osteopenia.
    • The requested therapy is for prevention of osteoporosis.

    Increasing Bone Mass in Prostate Cancer

    Authorization for 24 months may be granted when all of the following are met:

    ALL of the following

    • The member is a man with prostate cancer receiving androgen deprivation therapy (ADT).
    • The member is at high risk for fracture.
    • The requested therapy is to increase bone mass.

    Increasing Bone Mass in Breast Cancer

    Authorization for 24 months may be granted when all of the following are met:

    ALL of the following

    • The member is a woman with breast cancer receiving adjuvant aromatase inhibition therapy.
    • The member is at high risk for fracture.
    • The requested therapy is to increase bone mass.

    Glucocorticoid-Induced Osteoporosis

    Authorization for 24 months may be granted when all of the following are met:

    ALL of the following

    • The member is a man or woman with glucocorticoid-induced osteoporosis.
    • The member is at high risk for fracture.
    • The member is initiating or continuing systemic glucocorticoids at a daily dosage equivalent to 7.5 mg or greater of prednisone and is expected to remain on glucocorticoids for at least 6 months.

    Clinical Thresholds

    Glucocorticoid dosage
    Minimum daily dosage7.5 mg or greater prednisone-equivalent daily
    Expected glucocorticoid duration
    Minimum expected durationAt least 6 months
    Osteopenia study eligibility
    Lumbar spine BMD T-score-1 to -2.5

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the denosumab products addressed by this policy. Submit the HMSA medical specialty drug policy fax form through the HMSA specialty drug policy workflow.

    • Products include Bildyos (denosumab-nxxp), Bosaya (denosumab-kyqq), Conexxence (denosumab-bnht), Enoby (denosumab-qbde), Jubbonti (denosumab-bbdz), Ospomyv (denosumab-dssb), Osvyrti (denosumab-desu), Prolia (denosumab), and Stoboclo (denosumab-bmwo).
    • Formulary or preferred status does not eliminate the need for clinical prior authorization review.
    Step Therapy

    Preferred Product Exception

    Coverage for a non-preferred denosumab product requires a qualifying clinical exception to preferred Bildyos. The exception applies to members new to treatment with a non-preferred product and to requests for an indication that is FDA-approved for Bildyos.

    Clinical Background

    Denosumab is used to increase or preserve bone mineral density and reduce fracture risk in osteoporosis and in patients receiving therapies that accelerate bone loss. Covered uses include osteoporosis in postmenopausal women and men at high risk for fracture, osteoporosis prevention in osteopenic postmenopausal women, and treatment-related bone loss associated with androgen deprivation therapy for prostate cancer or adjuvant aromatase inhibitor therapy for breast cancer.

    The policy also recognizes glucocorticoid-induced osteoporosis in men and women at high risk for fracture. For applicable patients, systemic glucocorticoid therapy is defined as a daily dosage equivalent to 7.5 mg or greater of prednisone with expected treatment for at least 6 months.

    Policy Definitions

    High risk for fracture
    Prior osteoporotic fractureA history of osteoporotic fracture qualifies as high risk for fracture.
    Multiple risk factorsMultiple risk factors for fracture qualify as high risk.
    Other osteoporosis therapyFailure or intolerance of other available osteoporosis therapy qualifies as high risk.
    Benefit from therapy
    Disease stabilityBenefit from therapy includes disease stability.
    Disease improvementBenefit from therapy includes disease improvement.

    Initial Authorization

    Initial Osteoporosis Treatment

    Initial authorization may be granted for treatment of osteoporosis.

    The member is a man or postmenopausal woman with osteoporosis at high risk for fracture.Indefinite authorization

    High risk for fracture is defined by a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy where applicable.

    Initial Osteoporosis Prevention

    Initial authorization may be granted for prevention of osteoporosis.

    The member is an osteopenic postmenopausal woman.Indefinite authorization

    Coverage is for prevention of osteoporosis.

    Initial Therapy for Other Covered Indications

    Continuation Authorization

    Continuation for Osteoporosis

    All members, including new members, requesting continuation authorization must be currently receiving therapy with the requested agent.

    ALL of the following

    • The member is currently receiving therapy with the requested drug.
    • The requested drug is being used for osteoporosis treatment or osteoporosis prevention.
    • Benefit from therapy is demonstrated by ONE of the following

      • Disease stability.
      • Disease improvement.

    Preferred Product Sequence

    StepProductCoverage requirement
    1Bildyos (denosumab-nxxp) — preferredUse before a non-preferred denosumab product.
    2Non-preferred denosumab product: Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Prolia, or StobocloCoverage requires either a documented inadequate response or intolerable adverse event with Bildyos that was not an expected active-ingredient reaction, or treatment with the requested product within the past 365 days.

    Denosumab Reference Products

    Billing Rule

    Bildyos is preferred among denosumab products

    Bildyos (denosumab-nxxp) is the preferred denosumab product, including when compared with reference products such as Prolia. A non-preferred denosumab product requires a clinical exception or documented treatment with that product within the past 365 days.

    • Qualifying exceptions include inadequate response or an intolerable adverse event with Bildyos that was not an expected active-ingredient reaction.
    • Non-preferred products named in the policy include Bosaya, Conexxence, Enoby, Jubbonti, Ospomyv, Osvyrti, Prolia, and Stoboclo.
    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyProlia (denosumab) and Denosumab Biosimilars
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateOct 1, 2026
    Last ReviewJun 1, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization requests through the HMSA medical specialty drug policy website using the applicable fax form.
    SourceLink
    On This Page
    Covered IndicationsClinical ThresholdsAuthorization and Documentation RequirementsClinical BackgroundPolicy DefinitionsInitial AuthorizationContinuation AuthorizationPreferred Product SequenceDenosumab Reference Products
  1. The member has a documented inadequate response or intolerable adverse event with Bildyos, and the event is not an expected adverse event attributable to the active ingredient.
  2. Alternatively, the member received the requested non-preferred product within the past 365 days.
  3. Documentation Required

    Compendial Support for Other Indications

    For an indication not listed in the coverage criteria, submit supporting evidence from a Medicare-approved compendium. Other indications are assessed on an individual basis.

    • Document the requested indication and include the applicable compendial citation or supporting documentation.
    • Compendial support does not replace other applicable approval criteria or benefit requirements.
    Documentation Required

    Document the Non-Preferred Exception

    Requests for a non-preferred product must document why preferred Bildyos cannot be used, unless the member has received the requested product within the preceding 365 days.

    • Document an inadequate response to Bildyos or an intolerable adverse event with Bildyos.
    • Explain why the adverse event was not an expected reaction attributable to denosumab as described in prescribing information for the reference and biosimilar products.
    • For the prior-use exception, document treatment with the requested non-preferred product during the past 365 days.
    Documentation Required

    Continuation Therapy Documentation

    For continuation requests, document that the member is currently receiving the requested drug, that it is being used for a covered indication, and that the member is benefiting from therapy. Benefit means disease stability or disease improvement.

    • For osteoporosis treatment or prevention, indefinite authorization may be granted when all continuation criteria are met.
    • For all other enumerated indications, authorization may be granted for 12 months when all continuation criteria are met.

    Unsupported block type: documentation

    Denial Risk

    Criteria or Exclusion Not Met

    A request may be denied when the applicable approval criteria are not met or when the requested therapy is excluded under the member's benefit.

    • Verify the member's benefits and applicable exclusions before submitting the request.
    • Provide documentation addressing every required criterion for the requested indication, product, and phase of therapy.
    Denial Risk

    Unlisted Indication Lacks Compendial Support

    Indications not listed in the coverage criteria do not have automatic coverage. HMSA may deny the request or assess it individually when supporting evidence from a Medicare-approved compendium is not submitted or does not support the requested use.

    • Submit the compendial evidence with the prior authorization request.
    • Identify the compendium and the specific entry supporting the indication.
    Denial Risk

    Non-Preferred Exception Not Met

    A non-preferred denosumab request may be denied when the member does not meet either qualifying exception to preferred Bildyos.

    • No documented inadequate response or intolerable adverse event with Bildyos, or the documented event is an expected adverse event attributable to the active ingredient.
    • No documentation that the member received the requested non-preferred product within the past 365 days.
    Denial Risk

    Continuation Criteria Not Met

    A continuation request may be denied when the member is not currently receiving the requested drug, the drug is not being used for a covered indication, or the member is not receiving benefit from therapy.

    • For osteoporosis treatment or prevention, document current therapy, the osteoporosis indication, and disease stability or improvement.
    • For all other indications, document current therapy, an indication enumerated in the coverage criteria other than osteoporosis treatment or prevention, and disease stability or improvement.
    • If any required continuation element is absent or cannot be substantiated, continuation criteria are not met.

    Initial authorization may be granted for 24 months for the following indications.

    ONE of

    • The member is a man at high risk for fracture receiving androgen deprivation therapy (ADT) for prostate cancer, and treatment is requested to increase bone mass.
    • The member is a woman at high risk for fracture receiving adjuvant aromatase inhibition therapy for breast cancer, and treatment is requested to increase bone mass.
    • The member has glucocorticoid-induced osteoporosis and is at high risk for fracture; the member is initiating or continuing systemic glucocorticoids at a daily dosage equivalent to at least 7.5 mg of prednisone and is expected to remain on glucocorticoids for at least 6 months.>= 7.5 mg prednisone-equivalent daily; at least 6 months expected use

    Continuation for Other Indications

    All members, including new members, requesting continuation authorization must be currently receiving therapy with the requested agent.

    ALL of the following

    • The member is currently receiving therapy with the requested drug.
    • The requested drug is being used for an indication enumerated in the coverage criteria other than osteoporosis treatment or osteoporosis prevention.
    • Benefit from therapy is demonstrated by ONE of the following

      • Disease stability.
      • Disease improvement.